Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644755 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
A Phase 1 study of Sarcoma and Solid Tumors, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 7
- Study locations
NCT06644755: Recruiting Phase 1 study of Sarcoma and Solid Tumors, sponsored by Daiichi Sankyo.
NCT06644755 is a Phase 1 study of Sarcoma and Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 150 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06644755, a Phase 1 study of Sarcoma and Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 7
- Study locations
Study Summary
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG DS-2243a
Study Locations (7)
Other
- UZ Leuven Europe Leuven - Leuven
- Centre Leon Berard - Lyon
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) - Amsterdam
- Seoul National University Hospital - Seoul
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
What NCT06644755 shows while recruiting
NCT06644755 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which DS-2243a is the first listed.
NCT06644755 lists 7 locations in 4 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT06644755 about?
NCT06644755 is a clinical study titled "First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors". This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
What is the current status of trial NCT06644755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-11-14. Estimated completion is 2028-11-30.
What conditions does trial NCT06644755 study?
This clinical trial studies the following conditions: Sarcoma, Solid Tumors.
What interventions are being tested in trial NCT06644755?
The interventions under investigation include: DS-2243a (DRUG).
Who is sponsoring clinical trial NCT06644755?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644755 being conducted?
This trial has 7 study locations across Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06644755's enrollment target sits among peer trials
150 34th of 122 higher than 89 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy